Skip to content
Studies have shown that active fund managers routinely underperform the S&P500 index*
Home
Articles
WALL STREET X
Forecasts
Portfolios
Wall Street X
Articles
Forecasts
Portfolios
Search
Results for
{phrase}
(
{results_count}
of
{results_count_total}
)
Displaying
{results_count}
results of
{results_count_total}
Celldex Therapeutics, Inc. (NASDAQ: CLDX)
CLDX Stock Predictions and Ratings
WSX Rating:
STRONG SELL
WSX Forecast (1yr):
-85%
Analyst Rating:
STRONG BUY
Analyst Forecast (1yr):
76.40%
CLDX Stock Analysis
CLDX
PE Ratio:
CLDX
PEG Ratio:
Not Available
CLDX
Forward EPS Growth (12 month):
0.00%
CLDX
PS Ratio:
2287.4
CLDX
PSG Ratio:
9.4
CLDX
Forward Revenue Growth (12 month):
242.10%
CLDX Articles
No data was found